



## Clinical trial results:

### A Phase 2, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of LY2409021 Compared to Sitagliptin in Subjects with Type 2

## Diabetes Mellitus

### Summary

|                          |                   |
|--------------------------|-------------------|
| EudraCT number           | 2013-004275-12    |
| Trial protocol           | GR                |
| Global end of trial date | 28 September 2015 |

### Results information

|                                |               |
|--------------------------------|---------------|
| Result version number          | v1 (current)  |
| This version publication date  | 15 April 2018 |
| First version publication date | 15 April 2018 |

### Trial information

#### Trial identification

|                       |             |
|-----------------------|-------------|
| Sponsor protocol code | I1R-MC-GLDJ |
|-----------------------|-------------|

#### Additional study identifiers

|                                    |                     |
|------------------------------------|---------------------|
| ISRCTN number                      | -                   |
| ClinicalTrials.gov id (NCT number) | NCT02111096         |
| WHO universal trial number (UTN)   | -                   |
| Other trial identifiers            | Trial Number: 15286 |

Notes:

### Sponsors

|                              |                                                                          |
|------------------------------|--------------------------------------------------------------------------|
| Sponsor organisation name    | Eli Lilly and Company                                                    |
| Sponsor organisation address | Lilly Corporate Center , Indianapolis, IN, United States, 46285          |
| Public contact               | Available Mon-Fri 9 AM- 5 PM EST, Eli Lilly and Company, 1 877-CTLilly,  |
| Scientific contact           | Available Mon-Fri 9 AM- 5 PM EST, Eli Lilly and Company, 1 877-285-4559, |

Notes:

### Paediatric regulatory details

|                                                                      |    |
|----------------------------------------------------------------------|----|
| Is trial part of an agreed paediatric investigation plan (PIP)       | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

|                                                      |                   |
|------------------------------------------------------|-------------------|
| Analysis stage                                       | Final             |
| Date of interim/final analysis                       | 28 September 2015 |
| Is this the analysis of the primary completion data? | No                |
| Global end of trial reached?                         | Yes               |
| Global end of trial date                             | 28 September 2015 |
| Was the trial ended prematurely?                     | Yes               |

Notes:

## General information about the trial

Main objective of the trial:

The intent of this study is to assess the safety of LY2409021 in participants with Type 2 diabetes mellitus taking metformin and sulfonylurea as prescribed by their personal physician. The study treatment is expected to last 12 months (52 weeks).

Protection of trial subjects:

This study was conducted in accordance with International Conference on Harmonization (ICH) Good Clinical Practice, and the principles of the Declaration of Helsinki, in addition to following the laws and regulations of the country or countries in which a study is conducted.

Background therapy: -

Evidence for comparator: -

|                                                           |               |
|-----------------------------------------------------------|---------------|
| Actual start date of recruitment                          | 10 April 2014 |
| Long term follow-up planned                               | No            |
| Independent data monitoring committee (IDMC) involvement? | No            |

Notes:

## Population of trial subjects

### Subjects enrolled per country

|                                      |                    |
|--------------------------------------|--------------------|
| Country: Number of subjects enrolled | Greece: 16         |
| Country: Number of subjects enrolled | Puerto Rico: 26    |
| Country: Number of subjects enrolled | United States: 124 |
| Country: Number of subjects enrolled | Taiwan: 8          |
| Worldwide total number of subjects   | 174                |
| EEA total number of subjects         | 16                 |

Notes:

### Subjects enrolled per age group

|                                           |     |
|-------------------------------------------|-----|
| In utero                                  | 0   |
| Preterm newborn - gestational age < 37 wk | 0   |
| Newborns (0-27 days)                      | 0   |
| Infants and toddlers (28 days-23 months)  | 0   |
| Children (2-11 years)                     | 0   |
| Adolescents (12-17 years)                 | 0   |
| Adults (18-64 years)                      | 142 |

|                     |    |
|---------------------|----|
| From 65 to 84 years | 32 |
| 85 years and over   | 0  |

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

No text entered.

### Period 1

|                              |                                |
|------------------------------|--------------------------------|
| Period 1 title               | Overall Study (overall period) |
| Is this the baseline period? | Yes                            |
| Allocation method            | Randomised - controlled        |
| Blinding used                | Double blind                   |
| Roles blinded                | Subject, Investigator, Carer   |

### Arms

|                              |     |
|------------------------------|-----|
| Are arms mutually exclusive? | Yes |
|------------------------------|-----|

|                  |           |
|------------------|-----------|
| <b>Arm title</b> | LY2409021 |
|------------------|-----------|

Arm description:

20 milligrams (mg) LY2409021 given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician.

|                                        |              |
|----------------------------------------|--------------|
| Arm type                               | Experimental |
| Investigational medicinal product name | LY2409021    |
| Investigational medicinal product code |              |
| Other name                             |              |
| Pharmaceutical forms                   | Tablet       |
| Routes of administration               | Oral use     |

Dosage and administration details:

20 milligrams (mg) LY2409021 given orally once daily in the morning for 12 months (52 weeks). Participants remain on stable doses of metformin and sulfonylurea, as prescribed by their personal physician.

|                                        |           |
|----------------------------------------|-----------|
| Investigational medicinal product name | Metformin |
| Investigational medicinal product code |           |
| Other name                             |           |
| Pharmaceutical forms                   | Tablet    |
| Routes of administration               | Oral use  |

Dosage and administration details:

Metformin administered orally at doses prescribed by physician as background drug.

|                                        |              |
|----------------------------------------|--------------|
| Investigational medicinal product name | Sulfonylurea |
| Investigational medicinal product code |              |
| Other name                             |              |
| Pharmaceutical forms                   | Tablet       |
| Routes of administration               | Oral use     |

Dosage and administration details:

Sulfonylurea is administered orally as doses prescribed by personal physician.

|                  |             |
|------------------|-------------|
| <b>Arm title</b> | Sitagliptin |
|------------------|-------------|

Arm description:

100 mg sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician.

|          |                   |
|----------|-------------------|
| Arm type | Active comparator |
|----------|-------------------|

|                                        |             |
|----------------------------------------|-------------|
| Investigational medicinal product name | Sitagliptin |
| Investigational medicinal product code |             |
| Other name                             |             |
| Pharmaceutical forms                   | Tablet      |
| Routes of administration               | Oral use    |

Dosage and administration details:

100 mg sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remain on stable doses of metformin and sulfonylurea, as prescribed by their personal physician

|                                        |           |
|----------------------------------------|-----------|
| Investigational medicinal product name | Metformin |
| Investigational medicinal product code |           |
| Other name                             |           |
| Pharmaceutical forms                   | Tablet    |
| Routes of administration               | Oral use  |

Dosage and administration details:

Metformin administered orally at doses prescribed by physician as background drug.

|                                        |              |
|----------------------------------------|--------------|
| Investigational medicinal product name | Sulfonylurea |
| Investigational medicinal product code |              |
| Other name                             |              |
| Pharmaceutical forms                   | Tablet       |
| Routes of administration               | Oral use     |

Dosage and administration details:

Sulfonylurea is administered orally as doses prescribed by personal physician.

|                  |         |
|------------------|---------|
| <b>Arm title</b> | Placebo |
|------------------|---------|

Arm description:

Placebo matching LY2409021 and sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician.

|                                        |          |
|----------------------------------------|----------|
| Arm type                               | Placebo  |
| Investigational medicinal product name | Placebo  |
| Investigational medicinal product code |          |
| Other name                             |          |
| Pharmaceutical forms                   | Tablet   |
| Routes of administration               | Oral use |

Dosage and administration details:

Placebo matching LY2409021 and sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remain on stable doses of metformin and sulfonylurea, as prescribed by their personal physician.

|                                        |           |
|----------------------------------------|-----------|
| Investigational medicinal product name | Metformin |
| Investigational medicinal product code |           |
| Other name                             |           |
| Pharmaceutical forms                   | Tablet    |
| Routes of administration               | Oral use  |

Dosage and administration details:

Metformin administered orally at doses prescribed by physician as background drug.

|                                        |              |
|----------------------------------------|--------------|
| Investigational medicinal product name | Sulfonylurea |
| Investigational medicinal product code |              |
| Other name                             |              |
| Pharmaceutical forms                   | Tablet       |
| Routes of administration               | Oral use     |

Dosage and administration details:

Sulfonylurea is administered orally as doses prescribed by personal physician.

| <b>Number of subjects in period 1</b>  | LY2409021 | Sitagliptin | Placebo |
|----------------------------------------|-----------|-------------|---------|
| Started                                | 65        | 41          | 68      |
| Received at Least 1 Dose of Study Drug | 65        | 41          | 68      |
| Completed                              | 1         | 0           | 2       |
| Not completed                          | 64        | 41          | 66      |
| Lost to Follow Up                      | 1         | 1           | 1       |
| Terminated by Sponsor                  | 53        | 35          | 54      |
| Consent withdrawn by subject           | 4         | 2           | 8       |
| Physician decision                     | -         | 1           | -       |
| Non-Compliance with Study Drug         | 1         | 1           | -       |
| Adverse event, non-fatal               | 4         | 1           | 2       |
| Protocol deviation                     | 1         | -           | 1       |

## Baseline characteristics

### Reporting groups

|                                                                                                                                                                                                                                                             |             |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|
| Reporting group title                                                                                                                                                                                                                                       | LY2409021   |
| Reporting group description:<br>20 milligrams (mg) LY2409021 given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician.               |             |
| Reporting group title                                                                                                                                                                                                                                       | Sitagliptin |
| Reporting group description:<br>100 mg sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician.                         |             |
| Reporting group title                                                                                                                                                                                                                                       | Placebo     |
| Reporting group description:<br>Placebo matching LY2409021 and sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician. |             |

| Reporting group values                             | LY2409021 | Sitagliptin | Placebo |
|----------------------------------------------------|-----------|-------------|---------|
| Number of subjects                                 | 65        | 41          | 68      |
| Age categorical<br>Units: Subjects                 |           |             |         |
| In utero                                           | 0         | 0           | 0       |
| Preterm newborn infants (gestational age < 37 wks) | 0         | 0           | 0       |
| Newborns (0-27 days)                               | 0         | 0           | 0       |
| Infants and toddlers (28 days-23 months)           | 0         | 0           | 0       |
| Children (2-11 years)                              | 0         | 0           | 0       |
| Adolescents (12-17 years)                          | 0         | 0           | 0       |
| Adults (18-64 years)                               | 54        | 33          | 55      |
| From 65-84 years                                   | 11        | 8           | 13      |
| 85 years and over                                  | 0         | 0           | 0       |
| Age Continuous<br>Units: years                     |           |             |         |
| arithmetic mean                                    | 56.9      | 57.1        | 57.8    |
| standard deviation                                 | ± 8.33    | ± 8.99      | ± 8.21  |
| Gender, Male/Female<br>Units: Participants         |           |             |         |
| Female                                             | 24        | 10          | 31      |
| Male                                               | 41        | 31          | 37      |
| Ethnicity (NIH/OMB)<br>Units: Subjects             |           |             |         |
| Hispanic or Latino                                 | 30        | 19          | 42      |
| Not Hispanic or Latino                             | 34        | 21          | 25      |
| Unknown or Not Reported                            | 1         | 1           | 1       |
| Race (NIH/OMB)<br>Units: Subjects                  |           |             |         |
| American Indian or Alaska Native                   | 0         | 0           | 0       |
| Asian                                              | 4         | 2           | 5       |

|                                           |    |    |    |
|-------------------------------------------|----|----|----|
| Native Hawaiian or Other Pacific Islander | 0  | 0  | 0  |
| Black or African American                 | 14 | 6  | 11 |
| White                                     | 42 | 31 | 51 |
| More than one race                        | 5  | 2  | 1  |
| Unknown or Not Reported                   | 0  | 0  | 0  |
| Region of Enrollment                      |    |    |    |
| Units: Subjects                           |    |    |    |
| Greece                                    | 6  | 4  | 6  |
| Puerto Rico                               | 8  | 5  | 13 |
| United States                             | 48 | 31 | 45 |
| Taiwan                                    | 3  | 1  | 4  |

|                                                    |       |  |  |
|----------------------------------------------------|-------|--|--|
| <b>Reporting group values</b>                      | Total |  |  |
| Number of subjects                                 | 174   |  |  |
| Age categorical                                    |       |  |  |
| Units: Subjects                                    |       |  |  |
| In utero                                           | 0     |  |  |
| Preterm newborn infants (gestational age < 37 wks) | 0     |  |  |
| Newborns (0-27 days)                               | 0     |  |  |
| Infants and toddlers (28 days-23 months)           | 0     |  |  |
| Children (2-11 years)                              | 0     |  |  |
| Adolescents (12-17 years)                          | 0     |  |  |
| Adults (18-64 years)                               | 142   |  |  |
| From 65-84 years                                   | 32    |  |  |
| 85 years and over                                  | 0     |  |  |
| Age Continuous                                     |       |  |  |
| Units: years                                       |       |  |  |
| arithmetic mean                                    |       |  |  |
| standard deviation                                 | -     |  |  |
| Gender, Male/Female                                |       |  |  |
| Units: Participants                                |       |  |  |
| Female                                             | 65    |  |  |
| Male                                               | 109   |  |  |
| Ethnicity (NIH/OMB)                                |       |  |  |
| Units: Subjects                                    |       |  |  |
| Hispanic or Latino                                 | 91    |  |  |
| Not Hispanic or Latino                             | 80    |  |  |
| Unknown or Not Reported                            | 3     |  |  |
| Race (NIH/OMB)                                     |       |  |  |
| Units: Subjects                                    |       |  |  |
| American Indian or Alaska Native                   | 0     |  |  |
| Asian                                              | 11    |  |  |
| Native Hawaiian or Other Pacific Islander          | 0     |  |  |
| Black or African American                          | 31    |  |  |
| White                                              | 124   |  |  |
| More than one race                                 | 8     |  |  |
| Unknown or Not Reported                            | 0     |  |  |
| Region of Enrollment                               |       |  |  |
| Units: Subjects                                    |       |  |  |

|               |     |  |  |
|---------------|-----|--|--|
| Greece        | 16  |  |  |
| Puerto Rico   | 26  |  |  |
| United States | 124 |  |  |
| Taiwan        | 8   |  |  |

## End points

### End points reporting groups

|                                                                                                                                                                                                                                                             |             |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|
| Reporting group title                                                                                                                                                                                                                                       | LY2409021   |
| Reporting group description:<br>20 milligrams (mg) LY2409021 given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician.               |             |
| Reporting group title                                                                                                                                                                                                                                       | Sitagliptin |
| Reporting group description:<br>100 mg sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician.                         |             |
| Reporting group title                                                                                                                                                                                                                                       | Placebo     |
| Reporting group description:<br>Placebo matching LY2409021 and sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remained on stable doses of metformin and sulfonylurea, as prescribed by their personal physician. |             |

### Primary: Change from Baseline to 6 Months in Hepatic Fat Fraction

|                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                          |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                 | Change from Baseline to 6 Months in Hepatic Fat Fraction |
| End point description:<br>The hepatic fat fraction (HFF) was calculated by a core imaging laboratory from noncontrast magnetic resonance imaging (MRI) of the liver. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, country, baseline hemoglobin A1c (HbA1c) stratum ( $\leq 8.0\%$ , $> 8.0\%$ ), visit, baseline score, and treatment-by-visit. |                                                          |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                  | Primary                                                  |
| End point timeframe:<br>Baseline, 6 months                                                                                                                                                                                                                                                                                                                                                                      |                                                          |

| End point values                             | LY2409021           | Sitagliptin           | Placebo               |  |
|----------------------------------------------|---------------------|-----------------------|-----------------------|--|
| Subject group type                           | Reporting group     | Reporting group       | Reporting group       |  |
| Number of subjects analysed                  | 62 <sup>[1]</sup>   | 30 <sup>[2]</sup>     | 67 <sup>[3]</sup>     |  |
| Units: percentage                            |                     |                       |                       |  |
| least squares mean (confidence interval 95%) | 3.65 (2.13 to 5.17) | -0.07 (-1.94 to 1.79) | -0.79 (-2.28 to 0.70) |  |

Notes:

[1] - Participants who received 1 dose of study drug, MRI HFF baseline and 1 post-baseline data.

[2] - Participants who received 1 dose of study drug, MRI HFF baseline and 1 post-baseline data.

[3] - Participants who received 1 dose of study drug, MRI HFF baseline and 1 post-baseline data.

### Statistical analyses

|                            |                                               |
|----------------------------|-----------------------------------------------|
| Statistical analysis title | Statistical Analysis for Hepatic Fat Fraction |
| Comparison groups          | Placebo v LY2409021                           |

|                                         |               |
|-----------------------------------------|---------------|
| Number of subjects included in analysis | 129           |
| Analysis specification                  | Pre-specified |
| Analysis type                           |               |
| P-value                                 | < 0.001       |
| Method                                  | ANCOVA        |
| Confidence interval                     |               |
| sides                                   | 2-sided       |
| lower limit                             | 1.11          |
| upper limit                             | 3.4           |

### Secondary: Change from Baseline to 6 Months in Alanine Aminotransferase Levels

|                        |                                                                                                                                                                                                                                                                                            |
|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title        | Change from Baseline to 6 Months in Alanine Aminotransferase Levels                                                                                                                                                                                                                        |
| End point description: | Alanine aminotransferase (ALT) assessed by a central laboratory. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, country, baseline HbA1c stratum ( $\leq 8.0\%$ , $> 8.0\%$ ), visit, baseline score, and treatment-by-visit. |
| End point type         | Secondary                                                                                                                                                                                                                                                                                  |
| End point timeframe:   | Baseline, 6 months                                                                                                                                                                                                                                                                         |

| End point values                               | LY2409021         | Sitagliptin       | Placebo            |  |
|------------------------------------------------|-------------------|-------------------|--------------------|--|
| Subject group type                             | Reporting group   | Reporting group   | Reporting group    |  |
| Number of subjects analysed                    | 64 <sup>[4]</sup> | 39 <sup>[5]</sup> | 67 <sup>[6]</sup>  |  |
| Units: microgram per Liter ( $\mu\text{g/L}$ ) |                   |                   |                    |  |
| least squares mean (confidence interval 95%)   | 9.4 (4.6 to 14.2) | 2.6 (-3.1 to 8.3) | -1.3 (-6.0 to 3.4) |  |

Notes:

[4] - Randomized participants, 1 dose of study drug and evaluable data at baseline and 1 postbaseline.

[5] - Randomized participants, 1 dose of study drug and evaluable data at baseline and 1 postbaseline.

[6] - Randomized participants, 1 dose of study drug and evaluable data at baseline and 1 postbaseline.

### Statistical analyses

No statistical analyses for this end point

### Secondary: Frequency of Hepatobiliary Adverse Events of Special Interest (AESI)

|                        |                                                                                                                                                                                                                                                                                                                           |
|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title        | Frequency of Hepatobiliary Adverse Events of Special Interest (AESI)                                                                                                                                                                                                                                                      |
| End point description: | Number of participants with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 3 times the upper limit of normal at a post-baseline visit. A summary of other non-serious adverse events, (AEs, and all SAE 's), regardless of causality, is located in the Reported Adverse Events section. |
| End point type         | Secondary                                                                                                                                                                                                                                                                                                                 |
| End point timeframe:   | Baseline, 6 months                                                                                                                                                                                                                                                                                                        |

| End point values            | LY2409021         | Sitagliptin       | Placebo           |  |
|-----------------------------|-------------------|-------------------|-------------------|--|
| Subject group type          | Reporting group   | Reporting group   | Reporting group   |  |
| Number of subjects analysed | 65 <sup>[7]</sup> | 41 <sup>[8]</sup> | 68 <sup>[9]</sup> |  |
| Units: participants         |                   |                   |                   |  |
| number (not applicable)     | 0                 | 1                 | 1                 |  |

Notes:

[7] - All randomized participants who received at least 1 dose of study drug.

[8] - All randomized participants who received at least 1 dose of study drug.

[9] - All randomized participants who received at least 1 dose of study drug.

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline to 6 Months in Fasting Lipids Levels

|                 |                                                           |
|-----------------|-----------------------------------------------------------|
| End point title | Change from Baseline to 6 Months in Fasting Lipids Levels |
|-----------------|-----------------------------------------------------------|

End point description:

Lipid values (cholesterol, high density lipid (HDL) cholesterol, low density lipid (LDL) cholesterol, and triglycerides) assessed by a central laboratory. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, country, baseline HbA1c stratum ( $\leq 8.0\%$ ,  $>8.0\%$ ), visit, baseline score, and treatment-by-visit.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, 6 months

| End point values                             | LY2409021               | Sitagliptin              | Placebo                  |  |
|----------------------------------------------|-------------------------|--------------------------|--------------------------|--|
| Subject group type                           | Reporting group         | Reporting group          | Reporting group          |  |
| Number of subjects analysed                  | 65 <sup>[10]</sup>      | 41 <sup>[11]</sup>       | 68 <sup>[12]</sup>       |  |
| Units: millimole per liter (mmol/L)          |                         |                          |                          |  |
| least squares mean (confidence interval 95%) |                         |                          |                          |  |
| Cholesterol (n=58,38,60)                     | 0.468 (0.222 to 0.714)  | 0.006 (-0.282 to 0.295)  | 0.130 (-0.110 to 0.371)  |  |
| HDL Cholesterol (n=58,38,60)                 | 0.046 (-0.008 to 0.100) | 0.032 (-0.031 to 0.095)  | -0.021 (-0.032 to 0.074) |  |
| Triglycerides (n=58,38,60)                   | 0.375 (0.087 to 0.644)  | 0.078 (-0.264 to 0.420)  | 0.099 (-0.183 to 0.381)  |  |
| LDL Cholesterol (n=55,36,57)                 | 0.244 (0.019 to 0.486)  | -0.075 (-0.342 to 0.192) | 0.019 (-0.200 to 0.239)  |  |

Notes:

[10] - Participants who received 1 dose of study drug and have baseline and 1 post-baseline time point.

[11] - Participants who received 1 dose of study drug and have baseline and 1 post-baseline time point.

[12] - Participants who received 1 dose of study drug and have baseline and 1 post-baseline time point.

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline to 6 Months in Fasting Blood Glucagon

|                 |                                                            |
|-----------------|------------------------------------------------------------|
| End point title | Change from Baseline to 6 Months in Fasting Blood Glucagon |
|-----------------|------------------------------------------------------------|

End point description:

Glucagon values assessed by a central laboratory. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, country, baseline HbA1c stratum ( $\leq 8.0\%$ ,  $> 8.0\%$ ), visit, baseline score, and treatment-by-visit.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, 6 months

| End point values                             | LY2409021              | Sitagliptin           | Placebo               |  |
|----------------------------------------------|------------------------|-----------------------|-----------------------|--|
| Subject group type                           | Reporting group        | Reporting group       | Reporting group       |  |
| Number of subjects analysed                  | 65 <sup>[13]</sup>     | 41 <sup>[14]</sup>    | 68 <sup>[15]</sup>    |  |
| Units: picomole per liter (pmol/L)           |                        |                       |                       |  |
| least squares mean (confidence interval 95%) | 44.06 (36.36 to 51.76) | 3.38 (-5.64 to 12.41) | 5.05 (-2.50 to 12.60) |  |

Notes:

[13] - Participants who received 1 dose of study drug and have baseline and 1 post-baseline time point.

[14] - Participants who received 1 dose of study drug and have baseline and 1 post-baseline time point.

[15] - Participants who received 1 dose of study drug and have baseline and 1 post-baseline time point.

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline to 6 Months in Body Weight

|                 |                                                 |
|-----------------|-------------------------------------------------|
| End point title | Change from Baseline to 6 Months in Body Weight |
|-----------------|-------------------------------------------------|

End point description:

Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, country, baseline HbA1c stratum ( $\leq 8.0\%$ ,  $> 8.0\%$ ), visit, baseline score, and treatment-by-visit.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, 6 months

| End point values                             | LY2409021           | Sitagliptin           | Placebo               |  |
|----------------------------------------------|---------------------|-----------------------|-----------------------|--|
| Subject group type                           | Reporting group     | Reporting group       | Reporting group       |  |
| Number of subjects analysed                  | 64 <sup>[16]</sup>  | 40 <sup>[17]</sup>    | 68 <sup>[18]</sup>    |  |
| Units: kilograms (kg)                        |                     |                       |                       |  |
| least squares mean (confidence interval 90%) | 0.37 (0.12 to 0.63) | -0.08 (-0.39 to 0.22) | -0.05 (-0.30 to 0.20) |  |

Notes:

[16] - Randomized participants, 1 dose of study drug and evaluable data at baseline and 1 postbaseline.

[17] - Randomized participants, 1 dose of study drug and evaluable data at baseline and 1 postbaseline.

[18] - Randomized participants, 1 dose of study drug and evaluable data at baseline and 1 postbaseline.

## Statistical analyses

**Secondary: Change from Baseline to 6 Months in Hemoglobin A1c (HbA1c)**

|                 |                                                            |
|-----------------|------------------------------------------------------------|
| End point title | Change from Baseline to 6 Months in Hemoglobin A1c (HbA1c) |
|-----------------|------------------------------------------------------------|

End point description:

HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, country, visit, baseline score, and treatment-by-visit.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, 6 months

| End point values                             | LY2409021              | Sitagliptin            | Placebo              |  |
|----------------------------------------------|------------------------|------------------------|----------------------|--|
| Subject group type                           | Reporting group        | Reporting group        | Reporting group      |  |
| Number of subjects analysed                  | 63 <sup>[19]</sup>     | 40 <sup>[20]</sup>     | 68 <sup>[21]</sup>   |  |
| Units: percent of HbA1c                      |                        |                        |                      |  |
| least squares mean (confidence interval 95%) | -0.63 (-0.94 to -0.32) | -0.42 (-0.80 to -0.05) | 0.14 (-0.15 to 0.45) |  |

Notes:

[19] - Randomized participants, 1 dose of study drug and evaluable data at baseline and 1 postbaseline.

[20] - Randomized participants, 1 dose of study drug and evaluable data at baseline and 1 postbaseline.

[21] - Randomized participants, 1 dose of study drug and evaluable data at baseline and 1 postbaseline.

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Change from Baseline to 6 Months in Fasting Plasma Glucose**

|                 |                                                            |
|-----------------|------------------------------------------------------------|
| End point title | Change from Baseline to 6 Months in Fasting Plasma Glucose |
|-----------------|------------------------------------------------------------|

End point description:

Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, country, baseline HbA1c stratum ( $\leq 8.0\%$ ,  $> 8.0\%$ ), visit, baseline score, and treatment-by-visit.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, 6 months

| End point values                             | LY2409021             | Sitagliptin         | Placebo            |  |
|----------------------------------------------|-----------------------|---------------------|--------------------|--|
| Subject group type                           | Reporting group       | Reporting group     | Reporting group    |  |
| Number of subjects analysed                  | 65 <sup>[22]</sup>    | 41 <sup>[23]</sup>  | 68 <sup>[24]</sup> |  |
| Units: milligram per deciliter (mg/dL)       |                       |                     |                    |  |
| least squares mean (confidence interval 95%) | -20.5 (-34.3 to -6.6) | -9.4 (-26.3 to 7.4) | 6.6 (-7.0 to 20.2) |  |

Notes:

[22] - Participants who received 1 dose of study drug and have baseline and 1 post-baseline time point.

[23] - Participants who received 1 dose of study drug and have baseline and 1 post-baseline time point.

[24] - Participants who received 1 dose of study drug and have baseline and 1 post-baseline time point.

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline to 6 Months in Blood Pressure

|                 |                                                    |
|-----------------|----------------------------------------------------|
| End point title | Change from Baseline to 6 Months in Blood Pressure |
|-----------------|----------------------------------------------------|

End point description:

Seated systolic blood pressure (SBP) and seated diastolic blood pressure (DBP) were measured in triplicate throughout the study. At each visit, all available blood pressure measurements for a subject were averaged to provide the blood pressure for that visit. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, country, baseline HbA1c stratum ( $\leq 8.0\%$ ,  $>8.0\%$ ), visit, baseline score, and treatment-by-visit.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, 6 months

| End point values                             | LY2409021          | Sitagliptin        | Placebo            |  |
|----------------------------------------------|--------------------|--------------------|--------------------|--|
| Subject group type                           | Reporting group    | Reporting group    | Reporting group    |  |
| Number of subjects analysed                  | 63 <sup>[25]</sup> | 40 <sup>[26]</sup> | 68 <sup>[27]</sup> |  |
| Units: millimeters of mercury (mm/Hg)        |                    |                    |                    |  |
| least squares mean (confidence interval 95%) |                    |                    |                    |  |
| Systolic Blood Pressure                      | 6.1 (2.7 to 9.5)   | 1.1 (-2.9 to 5.2)  | 1.8 (-1.5 to 5.1)  |  |
| Diastolic Blood Pressure                     | 2.9 (0.7 to 5.0)   | 0.3 (-2.3 to 2.9)  | 1.5 (-0.6 to 3.6)  |  |

Notes:

[25] - Randomized participants, 1 dose of study drug and evaluable data at baseline and 1 postbaseline.

[26] - Randomized participants, 1 dose of study drug and evaluable data at baseline and 1 postbaseline.

[27] - Randomized participants, 1 dose of study drug and evaluable data at baseline and 1 postbaseline.

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline to 6 Months in Pulse Rate

|                 |                                                |
|-----------------|------------------------------------------------|
| End point title | Change from Baseline to 6 Months in Pulse Rate |
|-----------------|------------------------------------------------|

End point description:

Seated pulse rate was measured in triplicate throughout the study. At each visit, all available pulse measurements for a subject were averaged to provide the pulse for that visit. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, country, baseline HbA1c stratum ( $\leq 8.0\%$ ,  $>8.0\%$ ), visit, baseline score, and treatment-by-visit.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, 6 months

| End point values                             | LY2409021          | Sitagliptin        | Placebo            |  |
|----------------------------------------------|--------------------|--------------------|--------------------|--|
| Subject group type                           | Reporting group    | Reporting group    | Reporting group    |  |
| Number of subjects analysed                  | 63 <sup>[28]</sup> | 40 <sup>[29]</sup> | 68 <sup>[30]</sup> |  |
| Units: beats per minutes (bpm)               |                    |                    |                    |  |
| least squares mean (confidence interval 95%) | 1.5 (-0.6 to 3.7)  | 3.5 (0.9 to 6.0)   | 1.2 (-0.9 to 3.3)  |  |

Notes:

[28] - Randomized participants, 1 dose of study drug and evaluable data at baseline and 1 postbaseline.

[29] - Randomized participants, 1 dose of study drug and evaluable data at baseline and 1 postbaseline.

[30] - Randomized participants, 1 dose of study drug and evaluable data at baseline and 1 postbaseline.

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline to 6 Months in 7-Point Self-Monitoring of Blood Glucose (SMBG)

|                 |                                                                                     |
|-----------------|-------------------------------------------------------------------------------------|
| End point title | Change from Baseline to 6 Months in 7-Point Self-Monitoring of Blood Glucose (SMBG) |
|-----------------|-------------------------------------------------------------------------------------|

End point description:

7-point profile consists of pre-meal and 2-hour postprandial SMBG measurements for the morning, midday, and evening meals in 1 day and at 3 AM (nocturnal blood glucose measurement). Pre-meal measurements were taken before the subject began eating the meal. Participants recorded their glucose measurements in their study diaries.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, 6 months

| End point values                           | LY2409021          | Sitagliptin        | Placebo            |  |
|--------------------------------------------|--------------------|--------------------|--------------------|--|
| Subject group type                         | Reporting group    | Reporting group    | Reporting group    |  |
| Number of subjects analysed                | 65 <sup>[31]</sup> | 41 <sup>[32]</sup> | 68 <sup>[33]</sup> |  |
| Units: mg/dL                               |                    |                    |                    |  |
| arithmetic mean (standard deviation)       |                    |                    |                    |  |
| Morning Pre-Meal (n=52,28,48)              | -29.4 (± 40.36)    | -8.13 (± 31.25)    | -4.31 (± 26.69)    |  |
| Mid-day Pre Meal (n=51,28,47)              | -28.43 (± 41.13)   | -30.58 (± 48.98)   | -9.30 (± 51.08)    |  |
| Morning 2 Hour (Hr) Post Meal (n=48,28,44) | -38.8 (± 47.71)    | -30.76 (± 44.35)   | -18.28 (± 46.20)   |  |
| Midday 2 hr Post Meal (n=47,28,45)         | -24.22 (± 52.64)   | -25.20 (± 61.57)   | -10.49 (± 54.17)   |  |
| Evening Pre Meal (n=51,28,47)              | -24.58 (± 50.78)   | -16.78 (± 51.09)   | -14.13 (± 50.01)   |  |
| Evening 2 hr Post Meal (n=50,28,46)        | -28.36 (± 58.92)   | -21.12 (± 48.19)   | -9.50 (± 48.62)    |  |
| Three AM (n=48,27,45)                      | -22.78 (± 42.49)   | -20.12 (± 57.39)   | 0.88 (± 41.94)     |  |

Notes:

[31] - Randomized participants, 1 dose of study drug and evaluable data at baseline and 1 postbaseline.

[32] - Randomized participants, 1 dose of study drug and evaluable data at baseline and 1 postbaseline.

[33] - Randomized participants, 1 dose of study drug and evaluable data at baseline and 1 postbaseline.

## Statistical analyses

No statistical analyses for this end point

### Secondary: Population Pharmacokinetics: Apparent Clearance of LY2409021

|                 |                                                                              |
|-----------------|------------------------------------------------------------------------------|
| End point title | Population Pharmacokinetics: Apparent Clearance of LY2409021 <sup>[34]</sup> |
|-----------------|------------------------------------------------------------------------------|

End point description:

Reported as a Population Estimate with % Standard Errors of Estimation (SEE), 5th-95th confidence interval.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Day 1 Month 1, 3, 6, 9, predose, 1 hour postdose,

Notes:

[34] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint is only measuring for LY2409021 so only that arm is presented.

|                                  |                        |  |  |  |
|----------------------------------|------------------------|--|--|--|
| End point values                 | LY2409021              |  |  |  |
| Subject group type               | Reporting group        |  |  |  |
| Number of subjects analysed      | 65 <sup>[35]</sup>     |  |  |  |
| Units: Liters per hour (L/h)     |                        |  |  |  |
| number (confidence interval 95%) | 0.526 (0.454 to 0.598) |  |  |  |

Notes:

[35] - All randomized participants who received at least 1 dose of study drug and had evaluable PK data.

## Statistical analyses

No statistical analyses for this end point

### Secondary: Population Pharmacokinetics: Apparent Volume of Distribution of LY2409021

|                 |                                                                                           |
|-----------------|-------------------------------------------------------------------------------------------|
| End point title | Population Pharmacokinetics: Apparent Volume of Distribution of LY2409021 <sup>[36]</sup> |
|-----------------|-------------------------------------------------------------------------------------------|

End point description:

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Day 1 Month 1, 3, 6, 9, predose, 1 hour postdose,

Notes:

[36] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint is only measuring for LY2409021 so only that arm is presented.

|                                  |                     |  |  |  |
|----------------------------------|---------------------|--|--|--|
| <b>End point values</b>          | LY2409021           |  |  |  |
| Subject group type               | Reporting group     |  |  |  |
| Number of subjects analysed      | 65 <sup>[37]</sup>  |  |  |  |
| Units: Liters (L)                |                     |  |  |  |
| number (confidence interval 95%) | 31.9 (24.5 to 39.3) |  |  |  |

Notes:

[37] - All randomized participants who received at least 1 dose of study drug and had evaluable PK data.

## Statistical analyses

No statistical analyses for this end point

### Secondary: Rate of Hypoglycemic Events Adjusted per 30 Days

|                 |                                                  |
|-----------------|--------------------------------------------------|
| End point title | Rate of Hypoglycemic Events Adjusted per 30 Days |
|-----------------|--------------------------------------------------|

End point description:

Documented symptomatic hypoglycemia, an event during which typical symptoms of hypoglycemia are accompanied by a measured plasma glucose concentration  $\leq 70$  mg/dL ( $\leq 39$  mmol/L), is presented. Rate: (30 days) is calculated as: (number of episodes during the time period divided by the number of days during the time period) multiplied by 30.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline through 6 months

|                                   |                 |                 |                 |  |
|-----------------------------------|-----------------|-----------------|-----------------|--|
| <b>End point values</b>           | LY2409021       | Sitagliptin     | Placebo         |  |
| Subject group type                | Reporting group | Reporting group | Reporting group |  |
| Number of subjects analysed       | 64              | 40              | 68              |  |
| Units: number of episodes per day |                 |                 |                 |  |
| number (not applicable)           | 0.27            | 0.19            | 0.12            |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Participants with Hypoglycemic Events

|                 |                                                 |
|-----------------|-------------------------------------------------|
| End point title | Number of Participants with Hypoglycemic Events |
|-----------------|-------------------------------------------------|

End point description:

Documented symptomatic hypoglycemia, an event during which typical symptoms of hypoglycemia are accompanied by a measured plasma glucose concentration  $\leq 70$  mg/dL ( $\leq 39$  mmol/L), is presented. The number of subjects with an event are subjects who had at least one episode of documented symptomatic hypoglycemia during the time period.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline through 6 months

| <b>End point values</b>     | LY2409021          | Sitagliptin        | Placebo            |  |
|-----------------------------|--------------------|--------------------|--------------------|--|
| Subject group type          | Reporting group    | Reporting group    | Reporting group    |  |
| Number of subjects analysed | 64 <sup>[38]</sup> | 40 <sup>[39]</sup> | 68 <sup>[40]</sup> |  |
| Units: participants         |                    |                    |                    |  |
| number (not applicable)     | 20                 | 40                 | 68                 |  |

Notes:

[38] - Randomized participants, 1 dose of study drug and evaluable data at baseline and 1 postbaseline.

[39] - Randomized participants, 1 dose of study drug and evaluable data at baseline and 1 postbaseline.

[40] - Randomized participants, 1 dose of study drug and evaluable data at baseline and 1 postbaseline.

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Entire Study

Adverse event reporting additional description:

I1R-MC-GLDJ

|                 |            |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

### Dictionary used

|                 |        |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

|                    |      |
|--------------------|------|
| Dictionary version | 18.1 |
|--------------------|------|

### Reporting groups

|                       |                |
|-----------------------|----------------|
| Reporting group title | LY2409021 20mg |
|-----------------------|----------------|

Reporting group description: -

|                       |         |
|-----------------------|---------|
| Reporting group title | Placebo |
|-----------------------|---------|

Reporting group description: -

|                       |                   |
|-----------------------|-------------------|
| Reporting group title | Sitagliptin 100mg |
|-----------------------|-------------------|

Reporting group description: -

| Serious adverse events                                              | LY2409021 20mg | Placebo        | Sitagliptin 100mg |
|---------------------------------------------------------------------|----------------|----------------|-------------------|
| Total subjects affected by serious adverse events                   |                |                |                   |
| subjects affected / exposed                                         | 5 / 65 (7.69%) | 1 / 68 (1.47%) | 5 / 41 (12.20%)   |
| number of deaths (all causes)                                       | 0              | 0              | 0                 |
| number of deaths resulting from adverse events                      | 0              | 0              | 0                 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                |                |                   |
| renal cell carcinoma                                                |                |                |                   |
| alternative dictionary used: MedDRA 18.1                            |                |                |                   |
| subjects affected / exposed                                         | 1 / 65 (1.54%) | 0 / 68 (0.00%) | 0 / 41 (0.00%)    |
| occurrences causally related to treatment / all                     | 0 / 1          | 0 / 0          | 0 / 0             |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0          | 0 / 0             |
| Injury, poisoning and procedural complications                      |                |                |                   |
| femur fracture                                                      |                |                |                   |
| alternative dictionary used: MedDRA 18.1                            |                |                |                   |
| subjects affected / exposed                                         | 0 / 65 (0.00%) | 0 / 68 (0.00%) | 1 / 41 (2.44%)    |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0          | 0 / 1             |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0          | 0 / 0             |
| joint dislocation                                                   |                |                |                   |
| alternative dictionary used: MedDRA 18.1                            |                |                |                   |

|                                                 |                |                |                |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 65 (0.00%) | 0 / 68 (0.00%) | 1 / 41 (2.44%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Vascular disorders                              |                |                |                |
| hypertensive crisis                             |                |                |                |
| alternative dictionary used: MedDRA 18.1        |                |                |                |
| subjects affected / exposed                     | 1 / 65 (1.54%) | 0 / 68 (0.00%) | 0 / 41 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| malignant hypertension                          |                |                |                |
| alternative dictionary used: MedDRA 18.1        |                |                |                |
| subjects affected / exposed                     | 0 / 65 (0.00%) | 0 / 68 (0.00%) | 1 / 41 (2.44%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Cardiac disorders                               |                |                |                |
| acute coronary syndrome                         |                |                |                |
| alternative dictionary used: MedDRA 18.1        |                |                |                |
| subjects affected / exposed                     | 0 / 65 (0.00%) | 0 / 68 (0.00%) | 1 / 41 (2.44%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| atrial fibrillation                             |                |                |                |
| alternative dictionary used: MedDRA 18.1        |                |                |                |
| subjects affected / exposed                     | 0 / 65 (0.00%) | 0 / 68 (0.00%) | 1 / 41 (2.44%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| cardiac failure congestive                      |                |                |                |
| alternative dictionary used: MedDRA 18.1        |                |                |                |
| subjects affected / exposed                     | 0 / 65 (0.00%) | 0 / 68 (0.00%) | 1 / 41 (2.44%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| ventricular extrasystoles                       |                |                |                |
| alternative dictionary used: MedDRA 18.1        |                |                |                |

|                                                 |                |                |                |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 65 (0.00%) | 0 / 68 (0.00%) | 1 / 41 (2.44%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Gastrointestinal disorders                      |                |                |                |
| small intestinal obstruction                    |                |                |                |
| alternative dictionary used: MedDRA 18.1        |                |                |                |
| subjects affected / exposed                     | 0 / 65 (0.00%) | 1 / 68 (1.47%) | 0 / 41 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Respiratory, thoracic and mediastinal disorders |                |                |                |
| asthma                                          |                |                |                |
| alternative dictionary used: MedDRA 18.1        |                |                |                |
| subjects affected / exposed                     | 1 / 65 (1.54%) | 0 / 68 (0.00%) | 0 / 41 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Infections and infestations                     |                |                |                |
| abscess limb                                    |                |                |                |
| alternative dictionary used: MedDRA 18.1        |                |                |                |
| subjects affected / exposed                     | 0 / 65 (0.00%) | 0 / 68 (0.00%) | 1 / 41 (2.44%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| device related infection                        |                |                |                |
| alternative dictionary used: MedDRA 18.1        |                |                |                |
| subjects affected / exposed                     | 1 / 65 (1.54%) | 0 / 68 (0.00%) | 0 / 41 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| gastroenteritis                                 |                |                |                |
| alternative dictionary used: MedDRA 18.1        |                |                |                |
| subjects affected / exposed                     | 1 / 65 (1.54%) | 0 / 68 (0.00%) | 0 / 41 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| infectious colitis                              |                |                |                |
| alternative dictionary used: MedDRA 18.1        |                |                |                |

|                                                 |                |                |                |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed                     | 1 / 65 (1.54%) | 0 / 68 (0.00%) | 0 / 41 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| pneumonia                                       |                |                |                |
| alternative dictionary used: MedDRA 18.1        |                |                |                |
| subjects affected / exposed                     | 1 / 65 (1.54%) | 0 / 68 (0.00%) | 0 / 41 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |

Frequency threshold for reporting non-serious adverse events: 2 %

| <b>Non-serious adverse events</b>                                   | LY2409021 20mg   | Placebo          | Sitagliptin 100mg |
|---------------------------------------------------------------------|------------------|------------------|-------------------|
| Total subjects affected by non-serious adverse events               |                  |                  |                   |
| subjects affected / exposed                                         | 26 / 65 (40.00%) | 21 / 68 (30.88%) | 22 / 41 (53.66%)  |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                  |                  |                   |
| basal cell carcinoma                                                |                  |                  |                   |
| alternative dictionary used: MedDRA 18.1                            |                  |                  |                   |
| subjects affected / exposed                                         | 0 / 65 (0.00%)   | 0 / 68 (0.00%)   | 1 / 41 (2.44%)    |
| occurrences (all)                                                   | 0                | 0                | 1                 |
| colon adenoma                                                       |                  |                  |                   |
| alternative dictionary used: MedDRA 18.1                            |                  |                  |                   |
| subjects affected / exposed                                         | 0 / 65 (0.00%)   | 0 / 68 (0.00%)   | 1 / 41 (2.44%)    |
| occurrences (all)                                                   | 0                | 0                | 1                 |
| Vascular disorders                                                  |                  |                  |                   |
| hypertension                                                        |                  |                  |                   |
| alternative dictionary used: MedDRA 18.1                            |                  |                  |                   |
| subjects affected / exposed                                         | 2 / 65 (3.08%)   | 3 / 68 (4.41%)   | 1 / 41 (2.44%)    |
| occurrences (all)                                                   | 2                | 3                | 1                 |
| General disorders and administration site conditions                |                  |                  |                   |
| chest pain                                                          |                  |                  |                   |
| alternative dictionary used: MedDRA 18.1                            |                  |                  |                   |
| subjects affected / exposed                                         | 0 / 65 (0.00%)   | 0 / 68 (0.00%)   | 1 / 41 (2.44%)    |
| occurrences (all)                                                   | 0                | 0                | 1                 |
| fatigue                                                             |                  |                  |                   |

|                                                                                                                                                                                                                                                                                                                  |                                                               |                                                               |                                                               |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| <p>alternative dictionary used:<br/>MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>                                                                                                                                                                                                  | <p>2 / 65 (3.08%)</p> <p>2</p>                                | <p>0 / 68 (0.00%)</p> <p>0</p>                                | <p>1 / 41 (2.44%)</p> <p>1</p>                                |
| <p>oedema peripheral</p> <p>alternative dictionary used:<br/>MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>                                                                                                                                                                         | <p>0 / 65 (0.00%)</p> <p>0</p>                                | <p>0 / 68 (0.00%)</p> <p>0</p>                                | <p>2 / 41 (4.88%)</p> <p>3</p>                                |
| <p>pain</p> <p>alternative dictionary used:<br/>MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>                                                                                                                                                                                      | <p>0 / 65 (0.00%)</p> <p>0</p>                                | <p>0 / 68 (0.00%)</p> <p>0</p>                                | <p>1 / 41 (2.44%)</p> <p>1</p>                                |
| <p>polyp</p> <p>alternative dictionary used:<br/>MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>                                                                                                                                                                                     | <p>0 / 65 (0.00%)</p> <p>0</p>                                | <p>2 / 68 (2.94%)</p> <p>2</p>                                | <p>0 / 41 (0.00%)</p> <p>0</p>                                |
| <p>pyrexia</p> <p>alternative dictionary used:<br/>MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>                                                                                                                                                                                   | <p>0 / 65 (0.00%)</p> <p>0</p>                                | <p>0 / 68 (0.00%)</p> <p>0</p>                                | <p>1 / 41 (2.44%)</p> <p>1</p>                                |
| <p>Immune system disorders</p> <p>allergy to vaccine</p> <p>alternative dictionary used:<br/>MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>seasonal allergy</p> <p>alternative dictionary used:<br/>MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>0 / 65 (0.00%)</p> <p>0</p> <p>0 / 65 (0.00%)</p> <p>0</p> | <p>0 / 68 (0.00%)</p> <p>0</p> <p>0 / 68 (0.00%)</p> <p>0</p> | <p>1 / 41 (2.44%)</p> <p>1</p> <p>1 / 41 (2.44%)</p> <p>1</p> |
| <p>Reproductive system and breast disorders</p> <p>atrophic vulvovaginitis</p> <p>alternative dictionary used:<br/>MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>                                                                                                                   | <p>0 / 65 (0.00%)</p> <p>0</p>                                | <p>0 / 68 (0.00%)</p> <p>0</p>                                | <p>1 / 41 (2.44%)</p> <p>1</p>                                |
| <p>Respiratory, thoracic and mediastinal disorders</p>                                                                                                                                                                                                                                                           |                                                               |                                                               |                                                               |

|                                                                                                                                                         |                     |                     |                     |
|---------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|---------------------|---------------------|
| epistaxis<br>alternative dictionary used:<br>MedDRA 18.1<br>subjects affected / exposed<br>occurrences (all)                                            | 0 / 65 (0.00%)<br>0 | 0 / 68 (0.00%)<br>0 | 1 / 41 (2.44%)<br>1 |
| Psychiatric disorders<br>depression<br>alternative dictionary used:<br>MedDRA 18.1<br>subjects affected / exposed<br>occurrences (all)                  | 0 / 65 (0.00%)<br>0 | 0 / 68 (0.00%)<br>0 | 1 / 41 (2.44%)<br>1 |
| Investigations<br>alanine aminotransferase increased<br>alternative dictionary used:<br>MedDRA 18.1<br>subjects affected / exposed<br>occurrences (all) | 0 / 65 (0.00%)<br>0 | 1 / 68 (1.47%)<br>1 | 1 / 41 (2.44%)<br>1 |
| aspartate aminotransferase increased<br>alternative dictionary used:<br>MedDRA 18.1<br>subjects affected / exposed<br>occurrences (all)                 | 0 / 65 (0.00%)<br>0 | 0 / 68 (0.00%)<br>0 | 1 / 41 (2.44%)<br>1 |
| blood pressure diastolic increased<br>alternative dictionary used:<br>MedDRA 18.1<br>subjects affected / exposed<br>occurrences (all)                   | 2 / 65 (3.08%)<br>2 | 0 / 68 (0.00%)<br>0 | 1 / 41 (2.44%)<br>1 |
| free fatty acids increased<br>alternative dictionary used:<br>MedDRA 18.1<br>subjects affected / exposed<br>occurrences (all)                           | 2 / 65 (3.08%)<br>2 | 1 / 68 (1.47%)<br>1 | 1 / 41 (2.44%)<br>1 |
| glomerular filtration rate decreased<br>alternative dictionary used:<br>MedDRA 18.1<br>subjects affected / exposed<br>occurrences (all)                 | 1 / 65 (1.54%)<br>1 | 2 / 68 (2.94%)<br>2 | 1 / 41 (2.44%)<br>1 |
| heart rate increased<br>alternative dictionary used:<br>MedDRA 18.1<br>subjects affected / exposed<br>occurrences (all)                                 | 0 / 65 (0.00%)<br>0 | 0 / 68 (0.00%)<br>0 | 2 / 41 (4.88%)<br>2 |
| weight decreased                                                                                                                                        |                     |                     |                     |

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                              |                                                                                              |                                                                                              |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|
| <p>alternative dictionary used:<br/>MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>                                                                                                                                                                                                                                                                                                                                                   | <p>2 / 65 (3.08%)</p> <p>2</p>                                                               | <p>0 / 68 (0.00%)</p> <p>0</p>                                                               | <p>1 / 41 (2.44%)</p> <p>1</p>                                                               |
| <p>weight increased</p> <p>alternative dictionary used:<br/>MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>                                                                                                                                                                                                                                                                                                                           | <p>1 / 65 (1.54%)</p> <p>1</p>                                                               | <p>1 / 68 (1.47%)</p> <p>1</p>                                                               | <p>1 / 41 (2.44%)</p> <p>1</p>                                                               |
| <p>Congenital, familial and genetic disorders</p> <p>type v hyperlipidaemia</p> <p>alternative dictionary used:<br/>MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>                                                                                                                                                                                                                                                                   | <p>1 / 65 (1.54%)</p> <p>1</p>                                                               | <p>2 / 68 (2.94%)</p> <p>2</p>                                                               | <p>0 / 41 (0.00%)</p> <p>0</p>                                                               |
| <p>Cardiac disorders</p> <p>coronary artery disease</p> <p>alternative dictionary used:<br/>MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>sinus bradycardia</p> <p>alternative dictionary used:<br/>MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>ventricular extrasystoles</p> <p>alternative dictionary used:<br/>MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>0 / 65 (0.00%)</p> <p>0</p> <p>0 / 65 (0.00%)</p> <p>0</p> <p>0 / 65 (0.00%)</p> <p>0</p> | <p>0 / 68 (0.00%)</p> <p>0</p> <p>0 / 68 (0.00%)</p> <p>0</p> <p>0 / 68 (0.00%)</p> <p>0</p> | <p>1 / 41 (2.44%)</p> <p>1</p> <p>1 / 41 (2.44%)</p> <p>1</p> <p>1 / 41 (2.44%)</p> <p>1</p> |
| <p>Nervous system disorders</p> <p>carotid arteriosclerosis</p> <p>alternative dictionary used:<br/>MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>dizziness</p> <p>alternative dictionary used:<br/>MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>headache</p>                                                                                                                                  | <p>0 / 65 (0.00%)</p> <p>0</p> <p>4 / 65 (6.15%)</p> <p>5</p>                                | <p>0 / 68 (0.00%)</p> <p>0</p> <p>0 / 68 (0.00%)</p> <p>0</p>                                | <p>1 / 41 (2.44%)</p> <p>1</p> <p>0 / 41 (0.00%)</p> <p>0</p>                                |

|                                                                                                                                                     |                     |                     |                     |
|-----------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|---------------------|---------------------|
| alternative dictionary used:<br>MedDRA 18.1<br>subjects affected / exposed<br>occurrences (all)                                                     | 6 / 65 (9.23%)<br>8 | 1 / 68 (1.47%)<br>1 | 2 / 41 (4.88%)<br>8 |
| tension headache<br>alternative dictionary used:<br>MedDRA 18.1<br>subjects affected / exposed<br>occurrences (all)                                 | 0 / 65 (0.00%)<br>0 | 0 / 68 (0.00%)<br>0 | 1 / 41 (2.44%)<br>1 |
| Blood and lymphatic system disorders<br>anaemia<br>alternative dictionary used:<br>MedDRA 18.1<br>subjects affected / exposed<br>occurrences (all)  | 1 / 65 (1.54%)<br>1 | 0 / 68 (0.00%)<br>0 | 1 / 41 (2.44%)<br>1 |
| Ear and labyrinth disorders<br>cerumen impaction<br>alternative dictionary used:<br>MedDRA 18.1<br>subjects affected / exposed<br>occurrences (all) | 0 / 65 (0.00%)<br>0 | 0 / 68 (0.00%)<br>0 | 1 / 41 (2.44%)<br>1 |
| Eye disorders<br>blindness unilateral<br>alternative dictionary used:<br>MedDRA 18.1<br>subjects affected / exposed<br>occurrences (all)            | 0 / 65 (0.00%)<br>0 | 0 / 68 (0.00%)<br>0 | 1 / 41 (2.44%)<br>1 |
| diabetic retinal oedema<br>alternative dictionary used:<br>MedDRA 18.1<br>subjects affected / exposed<br>occurrences (all)                          | 0 / 65 (0.00%)<br>0 | 0 / 68 (0.00%)<br>0 | 1 / 41 (2.44%)<br>1 |
| eye swelling<br>alternative dictionary used:<br>MedDRA 18.1<br>subjects affected / exposed<br>occurrences (all)                                     | 0 / 65 (0.00%)<br>0 | 0 / 68 (0.00%)<br>0 | 1 / 41 (2.44%)<br>1 |
| glaucoma<br>alternative dictionary used:<br>MedDRA 18.1<br>subjects affected / exposed<br>occurrences (all)                                         | 0 / 65 (0.00%)<br>0 | 0 / 68 (0.00%)<br>0 | 1 / 41 (2.44%)<br>1 |
| Gastrointestinal disorders                                                                                                                          |                     |                     |                     |

|                                                                                                                                                       |                     |                     |                     |
|-------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|---------------------|---------------------|
| abdominal pain<br>alternative dictionary used:<br>MedDRA 18.1<br>subjects affected / exposed<br>occurrences (all)                                     | 1 / 65 (1.54%)<br>1 | 1 / 68 (1.47%)<br>1 | 1 / 41 (2.44%)<br>1 |
| constipation<br>alternative dictionary used:<br>MedDRA 18.1<br>subjects affected / exposed<br>occurrences (all)                                       | 2 / 65 (3.08%)<br>2 | 0 / 68 (0.00%)<br>0 | 3 / 41 (7.32%)<br>3 |
| diarrhoea<br>alternative dictionary used:<br>MedDRA 18.1<br>subjects affected / exposed<br>occurrences (all)                                          | 3 / 65 (4.62%)<br>3 | 3 / 68 (4.41%)<br>5 | 1 / 41 (2.44%)<br>1 |
| dry mouth<br>alternative dictionary used:<br>MedDRA 18.1<br>subjects affected / exposed<br>occurrences (all)                                          | 0 / 65 (0.00%)<br>0 | 0 / 68 (0.00%)<br>0 | 1 / 41 (2.44%)<br>1 |
| toothache<br>alternative dictionary used:<br>MedDRA 18.1<br>subjects affected / exposed<br>occurrences (all)                                          | 1 / 65 (1.54%)<br>1 | 2 / 68 (2.94%)<br>2 | 0 / 41 (0.00%)<br>0 |
| Hepatobiliary disorders<br>hepatic cyst<br>alternative dictionary used:<br>MedDRA 18.1<br>subjects affected / exposed<br>occurrences (all)            | 0 / 65 (0.00%)<br>0 | 0 / 68 (0.00%)<br>0 | 1 / 41 (2.44%)<br>1 |
| Skin and subcutaneous tissue disorders<br>pruritus<br>alternative dictionary used:<br>MedDRA 18.1<br>subjects affected / exposed<br>occurrences (all) | 0 / 65 (0.00%)<br>0 | 0 / 68 (0.00%)<br>0 | 1 / 41 (2.44%)<br>1 |
| rash<br>alternative dictionary used:<br>MedDRA 18.1<br>subjects affected / exposed<br>occurrences (all)                                               | 0 / 65 (0.00%)<br>0 | 0 / 68 (0.00%)<br>0 | 1 / 41 (2.44%)<br>1 |
| Renal and urinary disorders                                                                                                                           |                     |                     |                     |

|                                                                                                                                     |                     |                     |                     |
|-------------------------------------------------------------------------------------------------------------------------------------|---------------------|---------------------|---------------------|
| microalbuminuria<br>alternative dictionary used:<br>MedDRA 18.1<br>subjects affected / exposed<br>occurrences (all)                 | 0 / 65 (0.00%)<br>0 | 0 / 68 (0.00%)<br>0 | 1 / 41 (2.44%)<br>1 |
| nephrolithiasis<br>alternative dictionary used:<br>MedDRA 18.1<br>subjects affected / exposed<br>occurrences (all)                  | 0 / 65 (0.00%)<br>0 | 0 / 68 (0.00%)<br>0 | 1 / 41 (2.44%)<br>1 |
| Musculoskeletal and connective tissue disorders                                                                                     |                     |                     |                     |
| arthralgia<br>alternative dictionary used:<br>MedDRA 18.1<br>subjects affected / exposed<br>occurrences (all)                       | 2 / 65 (3.08%)<br>2 | 1 / 68 (1.47%)<br>2 | 0 / 41 (0.00%)<br>0 |
| arthritis<br>alternative dictionary used:<br>MedDRA 18.1<br>subjects affected / exposed<br>occurrences (all)                        | 0 / 65 (0.00%)<br>0 | 0 / 68 (0.00%)<br>0 | 1 / 41 (2.44%)<br>1 |
| back pain<br>alternative dictionary used:<br>MedDRA 18.1<br>subjects affected / exposed<br>occurrences (all)                        | 1 / 65 (1.54%)<br>1 | 1 / 68 (1.47%)<br>1 | 1 / 41 (2.44%)<br>1 |
| intervertebral disc degeneration<br>alternative dictionary used:<br>MedDRA 18.1<br>subjects affected / exposed<br>occurrences (all) | 0 / 65 (0.00%)<br>0 | 0 / 68 (0.00%)<br>0 | 1 / 41 (2.44%)<br>1 |
| musculoskeletal pain<br>alternative dictionary used:<br>MedDRA 18.1<br>subjects affected / exposed<br>occurrences (all)             | 2 / 65 (3.08%)<br>2 | 0 / 68 (0.00%)<br>0 | 1 / 41 (2.44%)<br>1 |
| musculoskeletal stiffness<br>alternative dictionary used:<br>MedDRA 18.1<br>subjects affected / exposed<br>occurrences (all)        | 0 / 65 (0.00%)<br>0 | 0 / 68 (0.00%)<br>0 | 1 / 41 (2.44%)<br>1 |
| myalgia<br>alternative dictionary used:                                                                                             |                     |                     |                     |

|                                             |                |                |                |
|---------------------------------------------|----------------|----------------|----------------|
| MedDRA 18.1                                 |                |                |                |
| subjects affected / exposed                 | 2 / 65 (3.08%) | 0 / 68 (0.00%) | 2 / 41 (4.88%) |
| occurrences (all)                           | 2              | 0              | 3              |
| pain in extremity                           |                |                |                |
| alternative dictionary used:<br>MedDRA 18.1 |                |                |                |
| subjects affected / exposed                 | 2 / 65 (3.08%) | 0 / 68 (0.00%) | 1 / 41 (2.44%) |
| occurrences (all)                           | 2              | 0              | 1              |
| tendonitis                                  |                |                |                |
| alternative dictionary used:<br>MedDRA 18.1 |                |                |                |
| subjects affected / exposed                 | 0 / 65 (0.00%) | 0 / 68 (0.00%) | 1 / 41 (2.44%) |
| occurrences (all)                           | 0              | 0              | 1              |
| Infections and infestations                 |                |                |                |
| bronchitis                                  |                |                |                |
| alternative dictionary used:<br>MedDRA 18.1 |                |                |                |
| subjects affected / exposed                 | 1 / 65 (1.54%) | 0 / 68 (0.00%) | 3 / 41 (7.32%) |
| occurrences (all)                           | 1              | 0              | 3              |
| conjunctivitis                              |                |                |                |
| alternative dictionary used:<br>MedDRA 18.1 |                |                |                |
| subjects affected / exposed                 | 0 / 65 (0.00%) | 0 / 68 (0.00%) | 1 / 41 (2.44%) |
| occurrences (all)                           | 0              | 0              | 1              |
| influenza                                   |                |                |                |
| alternative dictionary used:<br>MedDRA 18.1 |                |                |                |
| subjects affected / exposed                 | 2 / 65 (3.08%) | 1 / 68 (1.47%) | 2 / 41 (4.88%) |
| occurrences (all)                           | 2              | 1              | 2              |
| labyrinthitis                               |                |                |                |
| alternative dictionary used:<br>MedDRA 18.1 |                |                |                |
| subjects affected / exposed                 | 0 / 65 (0.00%) | 0 / 68 (0.00%) | 1 / 41 (2.44%) |
| occurrences (all)                           | 0              | 0              | 1              |
| nasopharyngitis                             |                |                |                |
| alternative dictionary used:<br>MedDRA 18.1 |                |                |                |
| subjects affected / exposed                 | 2 / 65 (3.08%) | 1 / 68 (1.47%) | 2 / 41 (4.88%) |
| occurrences (all)                           | 3              | 1              | 3              |
| pharyngitis                                 |                |                |                |
| alternative dictionary used:<br>MedDRA 18.1 |                |                |                |

|                                             |                |                |                |
|---------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed                 | 1 / 65 (1.54%) | 1 / 68 (1.47%) | 1 / 41 (2.44%) |
| occurrences (all)                           | 1              | 1              | 1              |
| pharyngitis streptococcal                   |                |                |                |
| alternative dictionary used:<br>MedDRA 18.1 |                |                |                |
| subjects affected / exposed                 | 0 / 65 (0.00%) | 0 / 68 (0.00%) | 1 / 41 (2.44%) |
| occurrences (all)                           | 0              | 0              | 1              |
| sinusitis                                   |                |                |                |
| alternative dictionary used:<br>MedDRA 18.1 |                |                |                |
| subjects affected / exposed                 | 2 / 65 (3.08%) | 1 / 68 (1.47%) | 0 / 41 (0.00%) |
| occurrences (all)                           | 2              | 1              | 0              |
| subcutaneous abscess                        |                |                |                |
| alternative dictionary used:<br>MedDRA 18.1 |                |                |                |
| subjects affected / exposed                 | 0 / 65 (0.00%) | 1 / 68 (1.47%) | 1 / 41 (2.44%) |
| occurrences (all)                           | 0              | 1              | 1              |
| upper respiratory tract infection           |                |                |                |
| alternative dictionary used:<br>MedDRA 18.1 |                |                |                |
| subjects affected / exposed                 | 4 / 65 (6.15%) | 3 / 68 (4.41%) | 3 / 41 (7.32%) |
| occurrences (all)                           | 6              | 4              | 3              |
| viral infection                             |                |                |                |
| alternative dictionary used:<br>MedDRA 18.1 |                |                |                |
| subjects affected / exposed                 | 2 / 65 (3.08%) | 0 / 68 (0.00%) | 0 / 41 (0.00%) |
| occurrences (all)                           | 4              | 0              | 0              |
| vulvovaginal candidiasis                    |                |                |                |
| alternative dictionary used:<br>MedDRA 18.1 |                |                |                |
| subjects affected / exposed                 | 0 / 65 (0.00%) | 0 / 68 (0.00%) | 1 / 41 (2.44%) |
| occurrences (all)                           | 0              | 0              | 1              |
| Metabolism and nutrition disorders          |                |                |                |
| abnormal weight gain                        |                |                |                |
| alternative dictionary used:<br>MedDRA 18.1 |                |                |                |
| subjects affected / exposed                 | 2 / 65 (3.08%) | 0 / 68 (0.00%) | 0 / 41 (0.00%) |
| occurrences (all)                           | 2              | 0              | 0              |
| hyperglycaemia                              |                |                |                |
| alternative dictionary used:<br>MedDRA 18.1 |                |                |                |

|                             |                |                |                |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 65 (0.00%) | 0 / 68 (0.00%) | 1 / 41 (2.44%) |
| occurrences (all)           | 0              | 0              | 1              |

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

|                                                                                                                      |
|----------------------------------------------------------------------------------------------------------------------|
| Terminated, The overall benefit-risk profile did not support continued development of LY2409021 for type 2 diabetes. |
|----------------------------------------------------------------------------------------------------------------------|

Notes: